<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:department>Norwich Medical School</gtr:department><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7"><gtr:id>88C5F7F9-8DCC-41C9-BC4F-F37DA01075C7</gtr:id><gtr:name>University of East Anglia</gtr:name><gtr:address><gtr:line1>Earlham Road</gtr:line1><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7TJ</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/921B6A79-8F6E-4312-8875-FBCB14B5FF40"><gtr:id>921B6A79-8F6E-4312-8875-FBCB14B5FF40</gtr:id><gtr:name>Plant Biosciences Limited (PBL)</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney Lane</gtr:line2><gtr:line4>Norwich</gtr:line4><gtr:line5>Norfolk</gtr:line5><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/93B41AB0-4170-47BF-8744-AECCB3CCCFC4"><gtr:id>93B41AB0-4170-47BF-8744-AECCB3CCCFC4</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>richard</gtr:otherNames><gtr:surname>Carding</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=BB%2FL004291%2F1"><gtr:id>B4F02D40-02A2-40B4-B542-618EB315CD11</gtr:id><gtr:title>Application of a commensal gut bacterium for the controlled delivery of heterologous proteins to the lower GI tract</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/L004291/1</gtr:grantReference><gtr:abstractText>Oral administration is the preferred route for delivering therapeutic proteins to the gut. To be effective, significant obstacles including minimising loss of activity during transit and controlling the dose delivered must be overcome. Our technology is designed to overcome these obstacles and uses the human commensal gut bacterium, Bacteroides ovatus (Bo) to deliver therapeutic agents in the gut in response to the dietary plant based sugar, xylan. This drug delivery platform technology will be further developed using a characterised model Bo strain producing a potent anti-inflammatory agent that can effectively treat and prevent gut inflammation. Determining optimal dosing and delivery regimens and the impact of Bo and xylan dosing on resident gut bacteria and demonstrating functionality in the large bowel will achieve this. The final output will be a robustly characterised delivery technology with pre-clinical proof of safety and functionality for the delivery of therapeutic proteins</gtr:abstractText><gtr:fund><gtr:end>2016-06-01</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2013-12-02</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>831444</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>Public engagement activities including IFR in the City seminars. Discussions with commercial biopharmaceutical companies for additional investment/sponsorship of the research. New IP has also emerged from the work.</gtr:description><gtr:firstYearOfImpact>2016</gtr:firstYearOfImpact><gtr:id>4A6D6CA3-7951-4F8E-AD13-5CBB05149283</gtr:id><gtr:impactTypes><gtr:impactType>Economic</gtr:impactType></gtr:impactTypes><gtr:sector>Healthcare,Manufacturing, including Industrial Biotechology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>Live bacteria cannot be used as drug delivery vehicles in humans due to genetic exchange and the reciprocal transfer of genes to and from the genetically engineered bacterium to other gut commensal bacteria. The extent of genetic exchange is considerable as demonstrated by the transfer and exchange of not only &amp;quot;marker&amp;quot; genes but also other unrelated and more distant genes within the chromosome of the GM-bacterium to other bacteria in the intestinal microbiota. Based upon the close similarity of the genetic makeup and process of genetic exchange amongst a wide range of commensal bacteria that are currently being used as GM-bacterial drug delivery vehicles we feel that the process of genetic exchange we have described in commensal Bacteroides spp. is applicable to other bacteria and in particular, Lactococcus app. that are being used in human trials.</gtr:description><gtr:exploitationPathways>They represent a word of caution to others interested in developing and using live bacteria to deliver therapeutic agents to patients or any other animal species.</gtr:exploitationPathways><gtr:id>3BFB7C45-661D-49D2-84AE-FA3F1D9B52DD</gtr:id><gtr:sectors><gtr:sector>Agriculture, Food and Drink,Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F5C2587B-2416-4C63-B6D9-D56ACA835B3A"><gtr:id>F5C2587B-2416-4C63-B6D9-D56ACA835B3A</gtr:id><gtr:title>Cephalosporinases associated with outer membrane vesicles released by Bacteroides spp. protect gut pathogens and commensals against ?-lactam antibiotics.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d4bd7aa5187b536aa43e71b484356d28"><gtr:id>d4bd7aa5187b536aa43e71b484356d28</gtr:id><gtr:otherNames>Stentz R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9586BEC4-1E80-4E99-AE2F-F3C249259C14"><gtr:id>9586BEC4-1E80-4E99-AE2F-F3C249259C14</gtr:id><gtr:title>A bacterial homolog of a eukaryotic inositol phosphate signaling enzyme mediates cross-kingdom dialog in the mammalian gut.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d4bd7aa5187b536aa43e71b484356d28"><gtr:id>d4bd7aa5187b536aa43e71b484356d28</gtr:id><gtr:otherNames>Stentz R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B0793E6C-4292-44A2-B005-A4D9429E7742"><gtr:id>B0793E6C-4292-44A2-B005-A4D9429E7742</gtr:id><gtr:title>A Novel Tightly Regulated Gene Expression System for the Human Intestinal Symbiont Bacteroides thetaiotaomicron.</gtr:title><gtr:parentPublicationTitle>Frontiers in microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d4b97b42fe4fae38d325bc793ab503b7"><gtr:id>d4b97b42fe4fae38d325bc793ab503b7</gtr:id><gtr:otherNames>Horn N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1664-302X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/679BCE39-FF2A-4670-BF60-6E688672A0D7"><gtr:id>679BCE39-FF2A-4670-BF60-6E688672A0D7</gtr:id><gtr:title>Defining the bacteroides ribosomal binding site.</gtr:title><gtr:parentPublicationTitle>Applied and environmental microbiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0dd294e3f26a329055fc5f94561ba867"><gtr:id>0dd294e3f26a329055fc5f94561ba867</gtr:id><gtr:otherNames>Wegmann U</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0099-2240</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/L004291/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>